Dr Reddy's, Intercept Pharmaceuticals enter into settlement agreement

19 Aug 2022 Evaluate

Dr Reddy's Laboratories and Intercept Pharmaceuticals Inc have entered into a settlement agreement, resolving the previously disclosed patent litigation to market a generic version of Ocaliva (obeticholic acid) 5 mg and 10 mg tablets in the USA. Ocaliva is used to treat a rare, chronic liver disease known as primary biliary cholangitis (PBC).

Under the terms of the agreement, Intercept granted Dr. Reddy’s a non-exclusive, non-sublicensable, non-transferable, royalty-free licence to commercialise its generic version of Ocaliva in the United States commencing on October 26, 2035, or earlier under certain circumstances.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1223.00 -17.00 (-1.37%)
28-Jan-2026 14:52 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1609.90
Dr. Reddys Lab 1223.00
Cipla 1321.30
Zydus Lifesciences 892.95
Lupin 2125.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×